Meta-analysis data from six randomized phase III trials in different cancers, including BC, suggested that variants in VEGF-A and EPAS1 are potential predictors of bevacizumab (anti-VEGF monoclonal antibody treatment) outcome [95]. Here, EPAS1 is linked to breast cancer.